Leukemia, Myelomonocytic, Acute: all 134 studies

Page 1 of 2. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT00801489Phase 2
• A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)TerminatedNCT05038800Phase 1Results posted
• DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaTerminatedNCT04752163Phase 1/2Results posted
• Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic SyndromeCompletedNCT04487106Phase 2Results posted
• Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AMLCompletedNCT03306264Phase 3Results posted
• Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)CompletedNCT02268253Phase 1/2Results posted
• Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid LeukemiaCompletedNCT02144675Phase 2Results posted
• AML Therapy With Irradiated Allogeneic CellsTerminatedNCT02105116Not applicableResults posted
• Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02085408Phase 3Results posted
• Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing ChemotherapyCompletedNCT02071901Phase 2Results posted
• Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02030405Phase 2Results posted
• Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT02029417Phase 2Results posted
• CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT02019069Phase 2Results posted
• Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity AssayCompletedNCT01872819Not applicableResults posted
• Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT01870596Phase 2Results posted
• Metformin+Cytarabine for the Treatment of Relapsed/Refractory AMLTerminatedNCT01849276Phase 1Results posted
• Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT01831232Not applicableResults posted
• Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic LeukemiaCompletedNCT01824693Phase 2Results posted
• A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of RuxolitinibCompletedNCT01776723Phase 1/2Results posted
• Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)CompletedNCT01736683Phase 2Results posted
• Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDSTerminatedNCT01607645Phase 2Results posted
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
• Tipifarnib in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT01361464Phase 2Results posted
• A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic LeukemiaCompletedNCT01350947Phase 2Results posted
• Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01349972Phase 2Results posted
• Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT01342887Phase 1/2Results posted
• Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid LeukemiaCompletedNCT01307579Phase 3Results posted
• Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell TransplantCompletedNCT01305200Phase 3Results posted
• AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01253447Phase 2Results posted
• Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid LeukemiaCompletedNCT01174043Phase 2Results posted
• Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid LeukemiaCompletedNCT01168219Phase 2Results posted
• Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01093586Phase 2Results posted
• Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell TransplantCompletedNCT01083706Phase 2Results posted
• A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).CompletedNCT00946647Phase 1/2Results posted
• Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AMLCompletedNCT00895934Phase 1/2Results posted
• Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisordersCompletedNCT00856388Not applicableResults posted
• Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00795002Phase 2Results posted
• Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00742625Phase 1/2Results posted
• Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaTerminatedNCT00708721Phase 1/2Results posted
• Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaTerminatedNCT00673153Phase 2Results posted
• Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid LeukemiaCompletedNCT00666588Phase 2Results posted
• Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaActive, not recruitingNCT00658814Phase 2Results posted
• Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00651261Phase 3Results posted
• Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00634244Phase 2Results posted
• Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid LeukemiaCompletedNCT00602771Phase 2Results posted
• Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep RCompletedNCT00534469Phase 2Results posted
• MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic LeukemiaCompletedNCT00462605Phase 2Results posted
• Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaCompletedNCT00451048Phase 2Results posted
• Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantCompletedNCT00408681Not applicableResults posted
• Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00407966Phase 2Results posted
• 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00381550Phase 2Results posted
• Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00369317Phase 3Results posted
• Lenalidomide in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00352365Phase 2Results posted
• Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00313586Phase 2Results posted
• Vorinostat in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00305773Phase 2Results posted
• Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)CompletedNCT00167219Phase 1/2Results posted
• Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00118352Phase 2Results posted
• Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
• Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid LeukemiaCompletedNCT00096122Phase 1/2Results posted
• Tipifarnib in Treating Patients With Acute Myeloid Leukemia in RemissionCompletedNCT00093470Phase 3Results posted
• Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in RemissionCompletedNCT00045435Phase 2Results posted
• Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib MesylateCompletedNCT00038675Not applicableResults posted
• Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic LeukemiaWithdrawnNCT06085638Phase 1/2
• Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy with Hypomethylating AgentsCompletedNCT05030675Phase 1
• Classical Monocyte Kinetics in Chronic Myelomonocytic LeukemiaCompletedNCT04775121Not applicable
• Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid LeukemiaStatus unknownNCT04687657Phase 1
• CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDSActive, not recruitingNCT04668885Phase 2
• Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)WithdrawnNCT02564536Phase 1
• Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)CompletedNCT02546284Phase 1
• A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid LeukemiaWithdrawnNCT02527174Phase 1
• Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative DisordersCompletedNCT02210858Phase 1/2
• Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoLTerminatedNCT02147873Phase 2
• MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02049801Phase 1
• Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT01904643Phase 1
• Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid LeukemiaCompletedNCT01839240Phase 1
• Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT01835288Phase 2
• Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01822015Early Phase 1
• Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01820624Phase 1
• Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid LeukemiaTerminatedNCT01801046Phase 1
• Studying Biomarkers in Samples From Younger Patients With Acute Myeloid LeukemiaCompletedNCT01642121
• Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT01627041Phase 2
• A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) PatientsCompletedNCT01613976Phase 1
• Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01555268Phase 1
• Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT01550185Phase 1
• Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction ChemotherapyTerminatedNCT01521936Phase 2
• Lenalidomide in Patients With Chronic Myelomonocytic LeukemiaStatus unknownNCT01368757Phase 1/2
• Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid LeukemiaTerminatedNCT01260714Phase 1
• Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic LeukemiaCompletedNCT01251627Phase 2
• Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive ChemotherapyCompletedNCT01235572Phase 2
• MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
• High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
• Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT01159301Phase 1
• Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01146210
• Veliparib and Temozolomide in Treating Patients With Acute LeukemiaCompletedNCT01139970Phase 1
• Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01127009Phase 1
• Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)CompletedNCT01098084Phase 2
• Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid LeukemiaCompletedNCT01076569
• Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
• Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)CompletedNCT01048034Phase 2
• Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01031368Phase 1

← Leukemia, Myelomonocytic, Acute overview